{"id":"W7048228274","doi":"","title":"Leap Therapeutics Reports Third Quarter 2017 Financial Results and Announces First Patient Dosed with DKN-01 and KEYTRUDA® (pembrolizumab) in Esophagogastric Cancer Trial","year":2017,"lang":"en","type":"other","venue":"","topic":"Photocathodes and Microchannel Plates","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Cancer; Clinical trial; MEDLINE","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002124302,0.000546383,0.0005549613,0.0006787268,0.0005900195,0.003690052,0.0007784086,0.001950431,0.1435635],"category_scores_gemma":[0.003464444,0.0002374038,0.001033897,0.0004342358,0.0004392138,0.001189026,0.000837878,0.004041731,0.04948065],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001869264,"about_ca_system_score_gemma":0.00308567,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001752047,"about_ca_topic_score_gemma":0.007023136,"domain_scores_codex":[0.9990637,0.0001701016,0.00003799083,0.00007304998,0.0004655746,0.0001896996],"domain_scores_gemma":[0.99739,0.0003962354,0.0002400909,0.0001493074,0.0005349465,0.001289566],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001965283,0.0004826849,0.0005308884,0.0001175914,0.00002978156,0.00009070186,0.000008141996,0.0001330203,0.0007029625,0.00157653,0.9298227,0.06453963],"study_design_scores_gemma":[0.003789135,0.001433743,0.002252405,0.0001772269,0.00006498657,0.0001930909,0.00002466466,0.0007891793,0.001693048,0.00292653,0.9866366,0.00001952733],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.01745619,0.009082324,0.003372009,0.1202878,0.02441156,0.001893307,0.05868822,0.003212086,0.7615965],"genre_scores_gemma":[0.04512835,0.009367732,0.003135798,0.04965524,0.01278375,0.00116877,0.03304143,0.001362741,0.8443562],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.1435635,"threshold_uncertainty_score":0.4802679,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01431025100854233,"score_gpt":0.231203908939876,"score_spread":0.2168936579313336,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}